Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783831 | 0.99 | AVPR1A (0.52) | AVPR1AAVPR2 | |
| SCHEMBL5834833 | 0.98 | AVPR1A (0.52) | AVPR1AAVPR2 | |
| SCHEMBL5834839 | 0.91 | AVPR1A (0.51) | AVPR1AAVPR2 | |
| SCHEMBL5783562 | 0.90 | AVPR1A (0.50) | AVPR1AAVPR2 | |
| SCHEMBL5787646 | 0.89 | AVPR1A (0.49) | AVPR1AAVPR2 | |
| SCHEMBL5781862 | 0.85 | AVPR1A (0.49) | AVPR1AAVPR2 | |
| SCHEMBL5835650 | 0.81 | AVPR1A (0.47) | AVPR1AAVPR2 | |
| SCHEMBL3535343 | 0.79 | AVPR1A (0.78) | AVPR1AAVPR2 | |
| SCHEMBL5786133 | 0.79 | AVPR1A (0.55) | AVPR1AAVPR2 | |
| SCHEMBL5785156 | 0.77 | AVPR2 (0.47) | AVPR1AAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109193-B2 | Tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-09-19 | — | — | US | disclosed |
| US-7064120-B2 | Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-06-20 | — | — | US | disclosed |
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055047-A1 | Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | OXTR, OPRL1, OPRK1 | AVPR1A 33/4885AVPR2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.